Guangzhou Yinming Biomedical Technology

Yinming Bio is a clinical-stage biotechnology company headquartered in Guangzhou, China, dedicated to developing innovative first-in-class treatments for diseases with significant unmet medical needs. The company's primary focus areas include ophthalmology, oncology, metabolic disorders, and anti-aging therapies. Its flagship program, QA102, is a small molecule currently undergoing Phase 2 clinical trials in the United States for dry age-related macular degeneration. Yinming Bio also advances a diverse pipeline of candidates targeting glaucoma and Stargardt disease, utilizing a proprietary drug discovery platform. Since its inception in 2019, the firm has secured substantial backing from leading global investors such as Hillhouse Capital and Qiming Venture Partners. The company maintains a global perspective with operations and clinical development activities spanning both China and the United States.